Hemosure and Its Related Studies

Hemosure^®, an one-step, easy to use product developed by Hemosure, Inc. based on its years of clinical study, is the latest technological breakthrough in Immunological Fecal Occult Blood Testing (IFOBT), and it is both FDA approved and CLIA waived. Hemosure^® employs a unique combination of monoclonal and polyclonal antibodies to detect only human blood in stool. As a result, abstinence of food and drug before taking this test is no longer necessary. These advantages can significantly enhance patient compliances.

In addition to the inherent specificity and sensitivity, Hemosure^® test can be performed by health care providers in hospitals, labs and private practices. No need to send fecal samples to the laboratory. Doctors can easily, quickly and accurately read the test results in less than 5 minutes. This new technology has greatly improved specificity, sensitivity, accuracy and cost-effectiveness of the fecal occult blood tests. Hemosure^® has unquestionably set a new standard on how future fecal occult blood testing is carried out. Click here to see the product presentation video.

In year 2001, Hemosure was proudly designated a sponsor in providing high quality immunological fecal occult blood tests for a large colorectal cancer-screening program; over 20,000 people in Beijing, China took part in the study. In April 2004, the Company sponsored another colorectal cancer-screening program in Hangzhou, China, in which over 60,000 people participated. Upon completion, these two recent studies together will surpass any previous clinically related studies in the world in terms of size and scope.